Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04504526 | Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases | recruiting | Early Phase 1 | 50 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06855121 | The Norwegian Immunotherapy in Multiple Myeloma Study(NIMMS) | recruiting | — | 400 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 |
| clinicaltrials |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | recruiting | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT07205315 | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia | recruiting | Early Phase 1 | 28 | Grit BiotechnologyINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07250646 | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | recruiting | Phase 1 | 28 | Aspera Biomedicines, Inc.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07712848 | DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | recruiting | Phase 3 | 291 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR(BIG-1) | recruiting | Phase 2 / Phase 3 | 3,100 | University Hospital, AngersOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT06810778 | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07246707 | KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01515527 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04968834 | Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens | recruiting | — | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05010772 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | recruiting | Phase 1 | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06102330 | Multicenter HomeVENT: Home Values and Experiences Navigation Track(HomeVENT) | recruiting | N/A | 600 | Johns Hopkins UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06469307 | Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)(DIVERSE) | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06498973 | Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | recruiting | Phase 1 | 43 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06533748 | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | recruiting | Phase 2 | 128 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07532525 | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | recruiting | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06928909 | Leukemia Adapted Protocol(LEAP) | recruiting | — | 30 | Baylor College of MedicineOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07128381 | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | recruiting | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level(iFIT) | recruiting | Phase 3 | 1,226 | University of LeedsOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705178 | More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)(MaximALL) | recruiting | N/A | 180 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04659616 | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 32 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05371808 | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | recruiting | — | 247 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06289673 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | recruiting | Phase 4 | 850 | St. Jude Children's Research HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06594445 | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML | recruiting | Phase 1 | 45 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03555851 | Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy | recruiting | — | 120 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06043011 | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms(RUBIN) | recruiting | — | 2,950 | iOMEDICO AGINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06870760 | Pre-malignant States to Hematologic Malignancies in Firefighters | recruiting | — | 300 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07228273 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | recruiting | Phase 2 | 102 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT05442216 | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents(TAGALONG) | recruiting | Phase 2 | 53 | Joshua ZeidnerOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06446661 | Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia | recruiting | N/A | 48 | University of ChicagoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695012 | CAR-T Cell Therapy for ALL(PAKCAR-ALL) | recruiting | Early Phase 1 | 10 | Dr. Zaineb AkramOTHER_GOV | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05945849 | CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML(CART33) | recruiting | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03810196 | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | recruiting | N/A | 50 | Children's Hospital of PhiladelphiaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07099443 | Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia(REBELLE) | recruiting | — | 60 | Nantes University HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05270200 | Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse | recruiting | Phase 1 / Phase 2 | 40 | Zhujiang HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07216443 | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 2 | 80 | Orca Biosystems, Inc.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07464951 | CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia(CART123) | recruiting | Phase 1 | 30 | Stephan Grupp MD PhDOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT01351545 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | recruiting | — | 99,999 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 21, 2026source: clinicaltrials